1Green BD,Mooney MH,Gault VA,et al.N-terminal His7-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity[J].J Endocrinol,2004,180(3):379-388.
2Sarrauste MC,Chavanieu A,Grassy G,et al.Structural requirements of the N-terminal region of GLP-1-[7-37] -NH2 for receptor interaction and cAMP production[J].Eur J Med Chem,2004,39(6):473-480.
3Chou JZ,Place GD,Waters DG,et al.A radioimmunoassay for LY315902,an analog of glucagon-like insulinotropic peptide,and its application in the study of canine pharmacokinetics[J].J Pharm Sci,1997,86:768-773.
4Lee S,Youn YS,Lee SH,et al.PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice[J].Diabetologia,2006,49(7):1608-1611.
5Youn YS,Chae SY,Lee S,et al.Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment:Insulinotropic activity,glucose-stabilizing capability,and proteolytic stability[J].Biochem Pharmacol,2007,73(1):84-93.
6Chae SY,Jin CH,Shin HJ.Preparation,characterization,and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery[J].Bioconjug Chem,2008,19(1):334-341.
7Chi Y,Zhang H,Huang W,et al.Microwave-assisted solid phase synthesis,PEGylation,and biological activity studies of glucagon-like peptide-1(7-36) amide[J].Bioorg Med Chem,2008,16(16):7607-7614.
8Tiessen RG,Castaigne JP,Dreyfus JF,et al.Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog,CJC-1131,in healthy and diabetic subjects[J].Int J Clin Pharmacol Ther,2008,46(9):443-452.
9Green BD,Flatt PR.Incretin hormone mimetics and analogues in diabetes therapeutics[J].Best Pract Res Clin Endocrinol Metab,2007,21(4):497-516.
10Soltani N,Kumar M,Glinka Y,et al.In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes[J].Gene The,2007,14(12):981-988.
2Gautier JF, Fetita S, Sobngwi E, et al. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes [J]. Diabetes Metab, 2005, 31(3pt1): 233- 242.
3Kluz J, Adamiec R. New therapeutic approach in patients with type 2 diabetes based on glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP) [J]. Postepy Hig Med Dosw,2006, 60:15-23.
4Schirra J, Katschinski M, Weidmann C, et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans [J] . J Clin Invest, 1996, 97:92-103.
3Van Delft J,Uttenthal L O.Identification of amidated forms of GLP-1in rat tissues using a highly sensitive radioimmunoassay[J].Regulatory Peptides,1997,70:191-198.
4Ovalle F.Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes[J].Clin Ther,2011,3(4):393-407.
5Borkiewicz P,Pawlak M,Mackowiak P.The results of prolonged action of GLP-1 on some metabolic parameters[J].Folia Biologica (Krakow),2011,59(1-2):13-17.
6Dharmalingam M,Sriram U,Baruah MP Liraglutide:A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2diabetes mellitus[J].Indian J Endocrinol Metab,2011,15 (1):9-17.
7Mentlein R.Dipeptidyl-peptidase Ⅳ (CD26)-role in the inactiveation of regulatory peptides[J].Regulatory Peptides,1999,85 (1):9-24.
8Doyle M E,Greig N H,Holloway H W,et al.Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent[J].Endocrinology,2001,142(10):4462-4468.
9Green B D,Mooney M H,Gault V A,et al.N-terminal His7-modification of glucagon-like peptide-1 (7-36) amide generates dipeptidyl peptidase Ⅳ-stable analogues with potent antihyperglycaemic activity[J].Journal of Endocrinology,2004,180:379-388.
10Juhl C B,Hollingdal M,Sturis J,et al.Bedtime administration of NN2211,a long-acting GLP-1 derivative,substantially reduces fasting and postprandial glycemia in Type 2 diabetes[J].Diabetes,2002,51:424-429.
